Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis

被引:265
|
作者
Ballell, Lluis [1 ]
Bates, Robert H. [1 ]
Young, Rob J. [2 ]
Alvarez-Gomez, Daniel [1 ]
Alvarez-Ruiz, Emilio [1 ]
Barroso, Vanessa [1 ]
Blanco, Delia [1 ]
Crespo, Benigno [1 ]
Escribano, Jaime [1 ]
Gonzalez, Ruben [1 ]
Lozano, Sonia [1 ]
Huss, Sophie [1 ]
Santos-Villarejo, Angel [1 ]
Julio Martin-Plaza, Jose [1 ]
Mendoza, Alfonso [1 ]
Jose Rebollo-Lopez, Maria [1 ]
Remuinan-Blanco, Modesto [1 ]
Luis Lavandera, Jose [1 ]
Perez-Herran, Esther [1 ]
Javier Gamo-Benito, Francisco [1 ]
Francisco Garcia-Bustos, Jose [1 ]
Barros, David [1 ]
Castro, Julia P. [1 ]
Cammack, Nicholas [1 ]
机构
[1] GlaxoSmithKline GSK, Madrid, Spain
[2] GlaxoSmithKline GSK, Med Res Ctr, CSC Med Chem, Stevenage SG1 2NY, Herts, England
关键词
drug discovery; high-throughput screening; open innovation; tuberculosis; MYCOBACTERIUM-TUBERCULOSIS; CHALLENGES; INHIBITORS;
D O I
10.1002/cmdc.201200428
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
With the aim of fuelling open-source, translational, early-stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible. A set of 177 potent non-cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compounds toward a chemical genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead-generation activities. Two additional drug-discovery-relevant datasets are included: a) a drug-like property analysis reflecting the latest lead-like guidelines and b) an early lead-generation package of the most promising hits within the clusters identified.
引用
收藏
页码:313 / 321
页数:9
相关论文
共 50 条
  • [1] Open source drug discovery: Small-molecule screening in academia
    Tolliday, Nicola
    JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (07) : 703 - 704
  • [2] Shape shifting leads to small-molecule allosteric drug discovery
    Lawrence, Sarah H.
    Ramirez, Ursula D.
    Tang, Lei
    Fazliyez, Farit
    Kundrat, Lenka
    Markham, George D.
    Jaffe, Eileen K.
    CHEMISTRY & BIOLOGY, 2008, 15 (06): : 586 - 596
  • [3] AutoMolDesigner for Antibiotic Discovery: An AI-Based Open-Source Software for Automated Design of Small-Molecule Antibiotics
    Shen, Tao
    Guo, Jiale
    Han, Zunsheng
    Zhang, Gao
    Liu, Qingxin
    Si, Xinxin
    Wang, Dongmei
    Wu, Song
    Xia, Jie
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2024, 64 (03) : 575 - 583
  • [4] Igniting Small-Molecule Drug Discovery
    Steinhagen, Henning
    CHEMMEDCHEM, 2016, 11 (02) : 148 - 149
  • [5] Antibody clamps pry open small-molecule drug discovery opportunities
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (04) : 247 - 248
  • [6] Antibody clamps pry open small-molecule drug discovery opportunities
    Asher Mullard
    Nature Reviews Drug Discovery, 2022, 21 : 247 - 248
  • [7] The Who, Why, and How of Small-Molecule Production in Invertebrate Microbiomes: Basic Insights Fueling Drug Discovery
    Kwan, Jason C.
    MSYSTEMS, 2018, 3 (02)
  • [8] Paving the way for small-molecule drug discovery
    Ma, Yu-Shui
    Xin, Rui
    Yang, Xiao-Li
    Shi, Yi
    Zhang, Dan-Dan
    Wang, Hui-Min
    Wang, Pei-Yao
    Liu, Ji-Bin
    Chu, Kai-Jian
    Fu, Da
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (03): : 853 - 870
  • [9] What is next for small-molecule drug discovery?
    Doweyko, Arthur M.
    Doweyko, Lidia M.
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (06) : 1029 - 1036
  • [10] Developing small-molecule libraries for drug discovery
    Gravert, DJ
    Janda, KD
    TRENDS IN BIOTECHNOLOGY, 1996, 14 (04) : 110 - 112